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Abstract
Background:  The use of antimalarial drug combinations with artemisinin derivatives is recommended to
overcome drug resistance in Plasmodium falciparum. The fixed combination of oral artemether-lumefantrine, an
artemisinin combination therapy (ACT) is highly effective and well tolerated. It is the only registered fixed
combination containing an artemisinin. The trial presented here was conducted to monitor the efficacy of the six-
dose regimen of artemether-lumefantrine (ALN) in an area of multi-drug resistance, along the Thai-Myanmar
border.
Methods: The trial was an open-label, two-arm, randomized study comparing artemether-lumefantrine and
mefloquine-artesunate for the treatment of uncomplicated falciparum malaria with 42 days of follow up. Parasite
genotyping by polymerase chain reaction (PCR) was used to distinguish recrudescent from newly acquired P.
falciparum infections. The PCR adjusted cure rates were evaluated by survival analysis.
Results: In 2001–2002 a total of 490 patients with slide confirmed uncomplicated P. falciparum malaria were
randomly assigned to receive artemether-lumefantrine (n = 245) or artesunate and mefloquine (n = 245) and were
followed for 42 days. All patients had rapid initial clinical and parasitological responses. In both groups, the PCR
adjusted cure rates by day 42 were high: 98.8% (95% CI 96.4, 99.6%) for artemether-lumefantrine and 96.3% (95%
CI 93.1, 98.0%) for artesunate-mefloquine. Both regimens were very well tolerated with no serious adverse
events observed attributable to either combination.
Conclusion: Overall, this study confirms that these two artemisinin-based combinations remain highly effective
and result in equivalent therapeutic responses in the treatment of highly drug-resistant falciparum malaria.
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Introduction
Multi-drug resistance of Plasmodium falciparum is a major
health problem in many countries and the number of
drugs available, effective and affordable is very limited
[1]. Along the Thai-Myanmar border, P. falciparum has
developed resistance to almost all available antimalarials
[2]. As in tuberculosis and HIV where resistance to drugs
is a serious issue, combination therapy has been applied
to malaria treatment [3]. The use of antimalarial drug
combinations with artemisinin derivatives has been advo-
cated and is now implemented in many countries [4]. An
extensive amount of information on efficacy and safety of
mefloquine has been reported and reviewed [5]. Artemisi-
nin or Qinghaosu is an extract of the medical plant Qing-
hao (Artemisia annua), which together with its derivatives,
artesunate and artemether are the most active antimalarial
compounds to date [6]. The artemisinin derivatives have
a rapid onset of therapeutic effect, where a single dose can
reduce the parasite biomass by a factor of approximately
104 every 48 hours. In addition, they have a very short ter-
minal elimination half-life of less than 2 hours [7]. Previ-
ous studies showed that once-daily administration with
artemisinin derivatives produced equivalent cure rates to
more frequent administration [8]. A three-day course of
artesunate combined with high dose mefloquine has
become the standard treatment combination for P. falci-
parum infections in Thailand [9]. Oral artesunate-meflo-
quine is the most widely used combination. More
recently, a fixed combination of oral artemether-lumefan-
trine (formerly known as benflumetol) has become avail-
able. Artemether is a methyl-ether derivative of
artemisinin. Lumefantrine is a racemic fluorine derivative
with high blood schizontocidal activity [10]. Both artem-
isinin combination therapies (ACT) are highly effective
and well tolerated [11]. However, resistance to meflo-
quine and/or to lumefantrine, would compromise both
combinations. Therefore it is important to monitor the
therapeutic efficacy and thus provide advance warning in
case of change. The trial presented here was conducted to
monitor the efficacy of the six-dose regimen of arte-
mether-lumefantrine combination given over three days
for the treatment of uncomplicated P. falciparum infec-
tions in adults and children on the western border of
Thailand.
Patients and methods
This study was conducted in the Maela and Mawker Tai
malaria clinics of the Shoklo Malaria Research Unit (Mae
Sot, Thailand)between July 2001 and June 2002. Patients
were recruited from two populations: displaced people of
the Karen ethnic minority and migrant workers living on
the western border of Thailand. This is an area of low and
unstable transmission of Plasmodium vivax and multi-
drug-resistant P. falciparum [12]. The trial was an open-
label, two-arm, randomized study comparing artemether-
lumefantrine andmefloquine-artesunate. This study was
approved by the Ethical and Scientific Committees of the
Faculty of Tropical Medicine, Mahidol University.
Procedures
Patients >10 kg in weight who had slide-confirmed acute
P. falciparum malaria were included in the study, provided
that they or their guardians gave fully informed written
consent intheir own language, they were not pregnant,
they had not received mefloquine in the previous 63 days
and there were no other clinical or laboratory signs of
severe illness and/or severe and complicated malaria [13].
If they gave written informed consent, they were allocated
randomly to receive either the six-dose regimen of arte-
mether-lumefantrine (Coartem® 20/120, Novartis Pharma
AG, Basel, Switzerland) or mefloquine (Lariam®, Hoff-
man-La Roche, Basel, Switzerland) plus artesunate (Gui-
lin Pharmaceutical Factory No.1, Guilin, China). At
enrolment (Day 0), a medical history was obtained, a full
physical examination was performed and blood was taken
for quantitative parasite counts and routine haematology
(finger prick blood sample for malaria smear and haema-
tocrit). All information was recorded on a standard case
record form. All patients were examined and blood
smears were taken daily until they became aparasitaemic,
and then weekly for 6 weeks. At each visit a questionnaire
on adverse events was completed. A blood smear was also
taken from any patient complaining of fever or symptoms
compatible with malaria during the follow-up period.
Parasite counts were determined on Giemsa-stained thick
and thin blood films. The person-gametocyte-weeks were
calculated per 1,000 person-weeks after excluding the epi-
sodes on admission and during treatment.
Drug regimens
Computerized randomization was in blocks of ten.
Patients allocated to artemether-lumefantrine group
(ALN) received the tablets at 0 and 8 hours and twice daily
for the following 2 days. Artemether-lumefantrine was
dispensed as a fixed dose combination tablet. Each tablet
contained 20 mg of artemether and 120 mg of lumefan-
trine. The number of tablets was given according to the
body weight. The minimum dosage for patients weighing
less than 15 kg was one tablet per dose; patients between
15 and 24 kg received two tablets, those between 25 and
34 kg received three tablets and patients 35 kg and above
were treated with four tablets per dose. Patients allocated
to artesunate-mefloquine group (MAS3) received artesu-
nate, 4 mg/kg oncedaily for 3 days (day 0 was the first day
of treatment), plus mefloquine, 15 mg/kg on day 1 and 10
mg/kg on day 2.
Each patient was given antipyretics and cooled by tepid
sponging if the tympanic temperature was equal or above
37.5°C before drug administration. Drug administrationMalaria Journal 2005, 4:46 http://www.malariajournal.com/content/4/1/46
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was observed in all patients and if vomiting occurred in
less than 30 min, administration of the full dose was
repeated, if vomiting occurred between 30 and 60 min,
half the dose was repeated. Patients treated with arte-
mether-lumefantrine were given a glass of chocolate milk
(200 ml) with each dose to increase absorption [14].
Outcome measures
The primary therapeutic outcome measure in this study
was the incidence of microscopically and genotypically
confirmedrecrudescent infections in both treatment
groups by day 42. Parasite genotyping by the polymerase
chain reaction (PCR) was used to distinguish recrudescent
from newly acquired P. falciparum infections. P. falciparum
infections were genotyped for allelic variation in three
polymorphic antigen loci, merozoite surface proteins 1
and 2 (MSP-1 and MSP-2) and glutamate rich protein
(GLURP), on admission and in case of parasite reappear-
ance [15,16]. Secondary measures were the immediate
treatment responses: parasite clearance, fever clearance,
incidence of adverse events, and degree of anaemia. The
sample size was calculated to detect a difference in failure
rates of 7 % between the two regimens with 90% CI and
80 % power assuming a 20% drop out.
Adverse events
Adverse events were symptoms or signs that were not pre-
senton admission and that developed after the start of
treatment. All adverse events, including those probably
related to malaria, were recording and compared among
treatment groups. The rates of early vomiting (<1 h) after
each dose and for each drug wererecorded and compared
among the groups in the analysis.
Management of recrudescent infections
Patients with uncomplicated recrudescent infections were
re-treated with artesunate, 2 mg/kg/day for 7 days;
patients >8 years oldalso received doxycycline, 4 mg/kg/
day for 7 days.
Statistical analysis
Data were analysed using SPSS for Windows, version 11.
Categorical data were compared using the Chi-square test
with Yates' correction or by Fisher's exact test, as appropri-
ate. Continuous variables conforming to a normal distri-
bution were compared using Student's t  test. Data not
normally distributed were log-transformed or compared
using the Mann-Whitney U test. The relative risks were cal-
culated using cross-tabulations. The rates of adverse
events at three different periods (days 1–2, days 3–7 and
days 14–42) were compared among treatment groups. For
each of the three periods, the events were counted only
once (e.g., if a patient vomited on day one and day two,
this was counted as one adverse event). The PCR-adjusted
cure rates were evaluated by survival analysis and com-
pared using the log-rank test. Patients for whom PCR gen-
otyping was either inconclusive or missing were censored
in the survival analysis on the day of parasite reappear-
ance. For all statistical tests the significance level (p) was
set at 0.05.
Results
Four hundred and ninety patients with uncomplicated P.
falciparum infections were enrolled between July 2001 and
May 2002. The artesunate-mefloquine and artemether-
lumefantrine groups included 245 patients each, the age
range for all patients was 2–72 years. Baseline characteris-
tics were similar in both groups (Table 1). In total, 484
patients (242 each group) were included in the final eval-
uation. Six patients (three in each group) were excluded
for the following reasons; withdrew consent (1), non-
compliance e.g. failure to complete trial treatment course
(4), failure to meet protocol criteria (1). Overall compli-
ance was good; around 99% of the patients in the study
(481 of 484) were seen at the day seven scheduled visit,
96.1% (465 patients) were seen at day 28 and 93.4% (452
patients) were seen at day 42.
Table 1: Demographic and baseline characteristics
ALN* (n = 245) MAS3** (n = 245)
Maela 100 100
Mawker Tai 145 145
Males, no. (%) 172 (70) 164 (67)
Age, years
Mean (SD) 23.2 (14.6) 23.6 (15.1)
Range 3–70 2–72
Age group, no. (%)
<5 10 (4.1) 8 (3.3)
5–14 81 (33.1) 75 (30.6)
>14 154 (62.9) 162 (66.1)
Weight, kg
Mean (SD) 42.4 (14.5) 42.3 (15.0)
Range 10–77 10–78
Temperature, °C
Mean (SD) 37.7 (1.0) 37.8 (1.1)
Range 35.6–40.5 35.9–41.0
Fevera, no (%) 136 (55.5) 142 (58.0)
Haematocrit, %
Mean (SD) 36.7 (5.9) 36.4 (5.8)
Range 21–52 20–51
Geometric mean (range) 8,047 7,570
parasite count (µl-1) (32–198,789) (16–198,789)
Hepatomegaly, no (%) 48 (19.6) 50 (20.4)
Splenomegaly, no (%) 70 (28.6) 57 (23.3)
* ALN = artemether-lumefantrine, ** MAS3 = artesunate-mefloquine 
aTympanic temperature ≥ 37.5°CMalaria Journal 2005, 4:46 http://www.malariajournal.com/content/4/1/46
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Clinical and parasitological findings
The initial responses to the two treatment groups were
similar. None of the patients developed severe malaria.
On admission, 55.0% (133/242) of the patients on ALN
and 57.9% (140/242) of the patients in the MAS3 group
had a tympanic temperature ≥ 37.5°C. All except three
patients had a normal temperature on day 3 (2 in ALN
and 1 in MAS3). There was no difference in fever clearance
times between the two treatment groups (Figure 1). Para-
site clearance times were short and most patients cleared
their parasitaemia by day two. Figure 2 shows the percent-
age of patients with positive slide for asexual P. falciparum
in both groups. By day three, four (1.8%) of 227 patients
in the artemether-lumefantrine recipients and three
(1.3%) of 238 artesunate-mefloquine recipients still had a
positive blood film (P > 0.05). Overall, 12.3 % of patients
were anaemic (haematocrit <30%) on admission, 10.8%
in ALN group and 13.8% in MAS3 group (P = 0.33). The
mean (SD) decrease in haematocrit value at day seven
from baseline was greater in the group receiving MAS3
than in the ALN group: 9.3% (SD,11.5%; 95% CI, 7.7% to
10.9%) compared with 6.7% (SD, 11.4%; 95% CI, 5.1 to
8.3%) respectively (P = 0.023).
During the 42-day follow-up period, 27 new P. falciparum
infections occurred among artemether-lumefantrine and
24 among artesunate-mefloquine recipients (P  > 0.05)
(Table 2). The PCR-adjusted cure rates by day 42 were
98.8% (95% CI, 96.4% to 99.6%) in the ALN group and
96.3% (95% CI, 93.1% to 98.0%) in the MAS3 group (P
= 0.08). PCR confirmed treatment failures were more
likely in children aged below 15 years than in adults (RR,
5.1; 95% CI, 1.4–18.7; P = 0.006). The mean age was 13.6
years (n = 12; SD = 8.5) in patients with treatment failure
and 23.7 years (n = 438; SD = 15.2) in successfully treated
patients. In this trial, only age group was independently
associated with treatment failure, but not other factors e.g.
higher parasitaemia (>10,000/µL); anaemia (haematocrit
<30%); fever (tympanic temp ≥ 37.5°C) on admission;
sites; treatment groups; early vomiting (within one hour
following drug administration). The mediantime to recru-
descence was comparable for MAS3 group (21 days; n = 9;
range, 14–28 days) and ALN group (28 days; n = 3; range,
21–42 days; P > 0.05).
Other parasitological findings
Of 452 patients, 119 (26.3%) had P. vivax parasitaemia
detected during follow up. There were significantly fewer
cases of vivax malaria in the MAS3 group (29 of 227) than
in the ALN group (90 of 225) (P < 0.001). The median
time to appearance of P. vivax parasitaemia was longer in
the MAS3 group (40 days; range, 13–43 days) than in the
ALN group (28 days; range, 14–43 days; P < 0.001).
Twenty patients (8.3%) in the artemether-lumefantrine
group and 19 (7.9%) in the artesunate-mefloquine group
had gametocytes detected during the first 3 days. All
except one patient in ALN group cleared gametocytes
within first week after start of treatment. After excluding
these, gametocytes developed (between day 7 and 42) in
1.2% (3/241) of ALN group and 1.3 (3/240) of MAS3
group. The person-gametocyte weeks were low and simi-
lar: 2.7 (95% CI, 0.6–7.8) per 1000 person-weeks for both
groups.
Adverse events
Both treatment regimens were well tolerated. No serious
adverse events were reported. Overall, 5/242(2.1%) of the
patients vomited one or more doses of medication in the
ALN group and 2/242(0.8%) of the MAS3 treated patients
Percentage of patients with fever (temperature > 37.5°C) Figure 1












































Percentage of patients with positive slide for asexual P. falci- parum forms Figure 2
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(RR, 2.5; 95% CI, 0.5–12.7; P = 0.45). The rates of early
vomiting (within one hour) of the drugs were very low
(around 2%) and did not differ among groups (one in
each group on day 2).
The most commonly reported and possibly drug-related
adverse events to both combination therapies were effects
on the gastrointestinal (abdominal pain, anorexia, nau-
sea, diarrhoea and late vomiting e.g. >1 h after administra-
tion of treatment) and central nervous system (headache,
dizziness). Figure 3 shows the proportions of possibly
drug-related adverse events of those who did not have
those symptoms at admission during follow-up in both
groups. Overall, there were less adverse events in ALN
group compared to MAS3, though the differences were
not statistically significant.
Discussion
The loss of affordable effective antimalarial drugs to resist-
ance represents a major threat to the people of malaria
endemic countries [1]. Using ineffective drugs with high
failure rates kills many and is unacceptable. A clear treat-
ment policy and readiness to use the new, more effective
artemisinin-based combination therapies (ACT) are cru-
cial [17]. Along the north-western border of Thailand,
where highly multi-drug resistant isolates of P. falciparum
are found, artesunate-mefloquine combination therapy
(MAS3) is the standard treatment regimen for uncompli-
cated falciparum malaria [9]. Early diagnosis and treat-
ment with an artemisinin-based drug combination of very
high efficacy that reduces gametocyte carriage, has led to a
marked decline in the incidence of falciparum malaria
and a reversal of the previous trend toward increasing
mefloquine resistance [18]. Artemisinin derivatives will
ensure rapid clinical and parasitological responses and are
remarkably effective, hence clinical deterioration is
extremely unusual. To optimize therapy, combination
with a slower-acting antimalarial drug is required. System-
atic use of ACT would help to delay the emergence of
Table 2: Treatment response.
Treatment group ALN* (n = 245) MAS3** (n = 245)
Compliance, no. (%)
Completed day 7 241 (99.6%) 240 (99.2%)
Completed day 28 232 (95.9%) 233 (96.3%)
Completed day 42 225 (93.0%) 227 (93.4%)
Cumulative proportion of patients with clinical failure, no (%)
Day 7 0 (0) 0 (0)
Day 28 13 (5.6) 14 (6.0)




Novel + recrudescent 1 1
Indeterminate/missing 1 1
PCR-adjusted cure rates, no. (%)
Day 7 0 (100) 0 (100)
Day 28 2 (99.1) 9(96.1)
Day 42 3 (98.8) 9 (96.3)
* ALN = artemether-lumefantrine, ** MAS3 = artesunate-mefloquine
Possibly drug-related adverse events (day 1 – day 42 Figure 3
Possibly drug-related adverse events (day 1 – day 42).
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resistance if the drug was used widely. However, the con-
tinued use of mefloquine monotherapy or with only 2
days of artesunate in this region, provides persistent selec-
tive pressure to continue the evolution of mefloquine
resistance, which could diminish the efficacy of the artesu-
nate-mefloquine combination and that of artemether-
lumefantrine.
Artemether-lumefantrine has been introduced recently for
oral treatment of uncomplicated falciparum  malaria. In
Thailand, several trials have been conducted with this
combination. The six-dose schedule provides sustained
blood lumefantrine levels and thus improved cure rates
[11]. Lumefantrine is highly lipophilic and the oral bioa-
vailability varies considerably between individuals and
increases greatly if the drug is administered after a meal
rich in fat [19].
The present trial reconfirmed the efficacy of the six-dose
regimen of artemether-lumefantrine given over three days
[20]. Both treatments in this study cleared fever and
parasitaemia promptly and reliably. Both treatments were
well tolerated and highly effective. Importantly 2/3 less P.
vivax  infections and 12 days longer median time to
appearance of P. vivax parasitaemia in the MAS3 group
were most probably due to the longer terminal half-life of
mefloquine compared to lumefantrine [21,22]. More data
on the safety and efficacy of artemether-lumefantrine in
very small children and pregnant women are needed.
Authors' contributions
RH carried out the study and analyzed the data. RH, EAA,
RMG, PS, TJ, NJW, FN conceived the study, participated in
its design and co-ordination and contributed to draft the
manuscript. LP, KLT assisted in collection of data. AB per-
formed the PCR experiments. All authors read and
approved the final manuscript.
Acknowledgements
We thank all the staff of the Shoklo Malaria Research Unit (SMRU) for their 
diligent work. This study was part of the Wellcome Trust-Mahidol Univer-
sity, Oxford Tropical Medicine Research Programme funded by the Well-
come Trust of Great Britain.
References
1. White NJ: Drug resistance in malaria.  Br Med Bull 1998,
54:703-715.
2. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, Luxemburger C, Web-
ster HK, Edstein M, Phaipun L, Thew KL, White NJ: Mefloquine-
resistant falciparum malaria on the Thai-Burmese border.
Lancet 1991, 337:1140-1143.
3. White NJ: Delaying antimalarial drug resistance with combi-
nation chemotherapy.  Parassitologia 1999, 41:301-308.
4. Looareesuwan S, Olliaro P, White NJ, Chongsuphajaisiddhi T, Sabcha-
roen A, Thimasarn K, Nosten F, Singhasivanon P, Supavej S, Khusmith
S, Wylings S, Kanyok T, Walsh D, Leggat PA, Doberstyn EB: Consen-
sus recommendation on the treatment of malaria in South-
east Asia.  Southeast Asian Journal of Tropical Medicine and Public
Health 1998, 29:355-360.
5. Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready
R, ter Kuile F, Kham A, Chongsuphajaisiddhi T, White NJ, Nosten F:
Adverse effects in patients with acute falciparum malaria
treated with artemisinin derivatives.  Am J Trop Med Hyg 1999,
60:547-555.
6. Hien TT, White NJ: Qinghaosu.  Lancet 1993, 341:603-608.
7. White NJ: Assessment of the pharmacodynamic properties of
antimalarial drugs in vivo.  Antimicrob Agents Chemother 1997,
41:1413-1422.
8. Luxemburger C, ter Kuile FO, Nosten F, Dolan G, Bradol JH, Phaipun
L, Chongsuphajaisiddhi T, White NJ: Single day mefloquine-
artesunate combination in the treatment of multi-drug
resistant falciparum malaria.  Trans R Soc Trop Med Hyg 1994,
88:213-217.
9. Nosten F, Luxemburger C, ter Kuile FO, Woodrow C, Eh JP, Chong-
suphajaisiddhi T, White NJ: Treatment of multidrug-resistant
Plasmodium falciparum malaria with 3-day artesunate-
mefloquine combination.  J Infect Dis 1994, 170:971-977.
10. Wernsdorfer WH, Landgraf B, Kilimali VA, Wernsdorfer G: Activity
of benflumetol and its enantiomers in fresh isolates of Plas-
modium falciparum from East Africa.  Acta Trop 1998, 70:9-15.
11. van Vugt MV, Wilairatana P, Gemperli B, Gathmann I, Phaipun L,
Brockman A, Luxemburger C, White NJ, Nosten F, Looareesuwan S:
Efficacy of six doses of artemether-lumefantrine (benflume-
tol) in multidrug-resistant Plasmodium falciparum malaria.
American Journal of Tropical Medicine and Hygiene 1999, 60:936-942.
12. Luxemburger C, Thwai KL, White NJ, Webster HK, Kyle DE, Maelan-
kirri L, Chongsuphajaisiddhi T, Nosten F: The epidemiology of
malaria in a Karen population on the western border of Thai-
land.  Transactions of the Royal Society of Tropical Medicine and Hygiene
1996, 90:105-111.
13. Severe and complicated malaria. World Health Organiza-
tion, Division of Control of Tropical Diseases.  Trans R Soc Trop
Med Hyg 1990, 84 Suppl 2:1-65.
14. White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics and
pharmacodynamics and pharmacodynamics of artemether-
lumefantrine.  Clin Pharmacokinet 1999, 37:105-125.
15. Brockman A, Paul RE, Anderson TJ, Hackford I, Phaiphun L,
Looareesuwan S, Nosten F, Day KP: Application of genetic mark-
ers to the identification of recrudescent Plasmodium falci-
parum infections on the northwestern border of Thailand.
American Journal of Tropical Medicine and Hygiene 1999, 60:14-21.
16. Jelinek T, Kilian AH, Westermeier A, Proll S, Kabagambe G, Noth-
durft HD, von Sonnenburg F, Loscher T: Population structure of
recrudescent Plasmodium falciparum isolates from western
Uganda.  Trop Med Int Health 1999, 4:476-480.
17. White NJ, Pongtavornpinyo W: The de novo selection of drug-
resistant malaria parasites.  Proc R Soc Lond B Biol Sci 2003,
270:545-554.
18. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman
A, McGready R, ter Kuile F, Looareesuwan S, White NJ: Effects of
artesunate-mefloquine combination on incidence of Plasmo-
dium falciparum malaria and mefloquine resistance in west-
ern Thailand: a prospective study.  Lancet 2000, 356:297-302.
19. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ: Pharma-
cokinetics and pharmacodynamics of lumefantrine (ben-
flumetol) in acute falciparum malaria.  Antimicrob Agents
Chemother 2000, 44:697-704.
20. van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L,
Gathmann I, Mull R, Brockman A, White NJ, Nosten F: Artemether-
lumefantrine for the treatment of multidrug-resistant falci-
parum malaria.  Trans R Soc Trop Med Hyg 2000, 94:545-548.
21. Karbwang J, Na-Bangchang K: Clinical application of mefloquine
pharmacokinetics in the treatment of P falciparum malaria.
Fundam Clin Pharmacol 1994, 8:491-502.
22. Ezzet F, Mull R, Karbwang J: Population pharmacokinetics and
therapeutic response of CGP 56697 (artemether + ben-
flumetol) in malaria patients.  Br J Clin Pharmacol 1998,
46:553-561.